Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease

Clinical Pharmacokinetics

Volumn 37, Issue 3, 1999, Pages 257-271

  Neef, Cees ^a   Van Laar, Teus ^b  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE;

BLOOD BRAIN BARRIER; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; DRUG TOLERANCE; DRUG TRANSFORMATION; DYSKINESIA; HUMAN; INTESTINE MUCOSA; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; IONTOPHORESIS; LIPOPHILICITY; LIVER METABOLISM; MAJOR CLINICAL STUDY; META ANALYSIS; PARKINSON DISEASE; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

ANTIPARKINSON AGENTS; APOMORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; LEVODOPA; PARKINSON DISEASE; TIME FACTORS;

EID: 0032851760     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937030-00004     Document Type: Review

References (52)

1. Parkinson J. An essay on the shaking palsy. London: Whittingham and Rowland, 1817
2. Weil E. De L'apomorphine dans certain troubles nerveux. Lyon Med 1884; 48: 411-9
3. Ernst AM. Relation between action of dopamine and apomorphine and the O-methylated derivatives upon the CNS. Psychopharmacologia 1965; 7: 391-9
4. Wachtel H. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J Neural Transm 1991; 3: 151-201
5. Cotzias GC, Papavasihou PS, Tolosa ES, et al. Treatment of Parkinson's disease with apomorphines. N Engl J Med 1976; 294: 567-72
6. Agid Y, Bonnet AM, Pollak P. et al. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet 1979; 1: 570-2
7. Stibe CMH, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988; 1: 403-6
8. Lundgren P, Landersjo L. Stability and stabilization apomorphine hydrochloride in aqueous solution. Acta Pharm Suec 1970; 7: 133-48
9. van Laar T, Jansen ENH, Essink AWG, et al. Intranasal apomorphine in parkinsonian on-off fluctuation. Arch Neurol 1992; 49: 482-4
10. van Laar T, Jansen ENH, Neef C, et al. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov Disord 1995; 10 (4): 433-9
11. van Laar T, Neef C, Danhof M, et al. A new sublingual formulation of apomorphine in the treatment of patients with Patkinson's disease. Mov Disord 1996; 11 (6): 633-8
12. Gancher ST, Nutt JG, Woodward WR. Absorption of apomorphine by various routes in parkinsonism. Mov Disord 1991; 6: 212-6
13. Priston MJ, Sewell GJ. Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. J Chromatogr B 1996; 681: 161-7
14. Essink AWG, Lohuis CPGG, Klein Elhorst JT, et al. Selective and quantitative isolation and determination of apomorphine in human plasma. J Chromatogr B 1991; 570: 419-24
15. Van der Geest R, Kruger P, Gubbens-Stibbe JM, et al. Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulphate conjugates in plasma and urine of patients with Parkinson's disease. J Chromatogr B 1997; 702: 131-41
16. Kaul PN, Brochman-Hanssen E, Way EL. Biological disposition of apomorphine. Urinary excretion and organ distribution of apomorphine. J Pharm Sci 1961; 50: 244-7
17. Kaul PN, Conway MW. Induction and inhibition of in vivo glucuronidation of apomorphine in mice. J Pharm Sci 1971; 60: 93-5
18. Missala K, Lal S, Sourkes TL. O-methylation of apomorphine and the metabolic prolongation of apomorphine-induced stereotyped behaviour. Eur J Pharmacol 1973; 22: 54-8
19. Burkman AM, Some kinetic and thermodynamic characteristics of apomorphine degra dation. J Pharm Sci 1965; 54: 325-6
20. Priston MJ, Sewell GJ. The analysis of apomorphine formulations for ambulatory infusions. Pharm Sci 1995; 1: 91-4
21. Goldman ME, Kehabian JW. Aporphine enantiomers: interactions with D1 and D2 dopamine receptors. Mol Pharmacol 1984; 25: 18-23
22. Van der Geest R, Van Laar T, Kruger PP. et al. Pharmacokinetics, enantiomer interconversion and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. Clin Neuropharmacol 1998; 21: 159-68
23. Danhof M, Mandema JW, Stijnen AM. Pharmacokinetic complexities of in vivo pharmacodynamic investigations. In: van Boxtel CJ, Holford NHG, Danhof M, editors. The in vivo study of drug action concepts and applications of kinetic-dynamic modeling. Amsterdam: Elsevier Science Publishers, 1992; 31-60
24. Przedborski S, Levivier M, Raftopoulus C, et al. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov Disord 1995; 10: 28-36
25. Gancher ST, Woodward WR, Gliessman P, et al. The short-duration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonism. Ann Neurol 1990; 17: 45-52
26. Hofstee DJ, Neef C, van Laar T, et al. Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses. Clin Neuropharmacol 1994; 17: 45-52
27. Dewey RB, Maraganore DM, Ahlskog JE, et al. A double-blind placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-slates in Parkinson's disease. Mov Disord 1998; 13: 782-7
28. Lees AJ, Montastrue JL, Turjanski N, et al. Sublingual apomorphine in Parkinson's disease [comments]. J Neurol Neurosurg Psychiatry 1989; 51: 1440
29. Gancher ST, Woodward WR, Boucher B. et al. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989; 26: 232-8
30. Gancher GT, Nutt JG, Woodward WR. Time course of tolerance to apomorphine in parkinsonism. Clin Pharmacol Ther 1992; 52: 504-10
31. Nicolle E, Pollak P, Serre-Debeauvais F, et al. Pharmacokinetics of apomorphine in parkinsonian patients. Fundam Clin Pharmacol 1993; 7; 245-52
32. Van Laar T, Van der Geest R, Danhof M, et al. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease. Clin Neuropharmacol 1998; 2l: 152-8
33. Verhagen Metman L, Locatelli ER, Bravi D, et al. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997; 48: 369-72
34. Pollak P, Champay AS, Hommel M, et al. Subcutaneous apo morphine in Parkinson's disease [letter]. J Neurol Neurosurg Psychiatry 1989; 52: 544
35. Corboy DL, Wagner ML, Sage JL Apomorphine for motor fluctuations and freezing in Parkinson's disease. Ann Pharmacother 1995; 29: 282-8
36. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease; response to chronic administration for up to five years. Mov Disord 1993; 6: 165-70
37. Kraegen EW, Chrischolm DJ, Pharmacokinetics of insulin: implications for continuous subcutaneous insulin infusion therapy. Clin Pharmacokinet 1985; 10: 303-14
38. Sam E, Sarre S, Michotte Y, et al. Distribution of apomorphine enantiomers in plasma, brain tissue and striatal extracellular fluid. Eur J Pharmacol 1997; 329: 9-15
39. Neef C, Jelliffe RW, Van Laar T, et al. Population pharmacokinetics of apomorphine in patients with Parkinson's disease. Drug Invest 1994; 7: 183-90
40. Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 96-101
41. Durif F, Jeanneau E, Serre-Deheauvais D, et al. Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease. Eur J Clin Pharmacol 1991; 41: 493-4
42. Hughes AJ, Bishop S, Lees AJ, et al. Rectal apomorphine in Parkinson's disease. Lancet 1991; 337: 118
43. Van der Geest R, Danhof M, Bodde HE. Iontophoretic delivery of apomorphine: in vitro optimisation and validation. Pharm Res 1997; 14: 1797-802
44. Van der Geest R, Van Laar T, Gubbens-Stibbe JM, et al. Iontophoretic delivery of R-apomorphine: an in vivo study in patients with Parkinsons disease. Pharm Res 1997; 14: 1803-9
45. Hughes AJ, Lees AJ, Stern GM. The motor response to sequential apomorphine in parkinsonian fluctuations. J Neurol Neurosurg Psychiatry 1991; 54: 358-60
46. Grandas F, Gancher S, Lera G, et al. Time interval between repeated injections conditions: the duration of motor improvement to apomorphine in Parkinson's disease. Neurology 1992; 42: 1287-90
47. Gancher ST, Woodward WR, Nutt JG. Apomorphine tolerance in Parkinson's disease: lack of a dose effect. Clin Neuropharmacol 1996; 19: 59-64
48. Baas H, Harder S, Burklin F, et al. Pharmacodynamics of levodopa co-administered with apomorphine in Parkinsonian patients with end-of-dose motor fluctuations. Clin Neuropharmacol 1998; 2l: 86-92
49. Gjedde A, Wong DF. Modeling neuroreceptor binding of radioligands in vivo. In: Frost JJ, Wagner HN, editors. Quantitative imaging: neuroreceptors, neurotransmitters and enzymes. New York: Raven Press, 1990: 51-80
50. Kapoor R, Turjanski M, Frankel, et al. Intranasal apomorphine: a new treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 1015
51. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharamcological law and order. Ann Neurol 1996; 39: 561-73
52. Harder S, Baas H, Röger S, et al. PK-PD relationship of apomorphine in patients with Parkinson's Disease [abstract PIII-77]. Clin Pharmacol Ther 1995; 59 (2): 207